PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
16.61%
Some net income increase while CRVO is negative at -14.32%. John Neff would see a short-term edge over the struggling competitor.
4.17%
Some D&A expansion while CRVO is negative at -1.96%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-100.00%
Negative yoy deferred tax while CRVO stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-2.08%
Negative yoy SBC while CRVO is 19.40%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-115.45%
Both reduce yoy usage, with CRVO at -250.43%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.13%
Both negative yoy AP, with CRVO at -27.34%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-68.80%
Both reduce yoy usage, with CRVO at -156.26%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
119.47%
Growth of 119.47% while CRVO is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might reflect intangible expansions or partial write-offs.
9.84%
Some CFO growth while CRVO is negative at -52.49%. John Neff would note a short-term liquidity lead over the competitor.
98.37%
CapEx growth of 98.37% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.37%
We expand invests by 98.37% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
64.41%
Debt repayment growth of 64.41% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-34.38%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.